Trial Profile
Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Aug 2013
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.